To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: New NICE Prostate Cancer Guideline Focuses on Quality of Life Issues URL: http://www.pslgroup.com/dg/21DB76.htm Doctor's Guide February 27, 2008
LONDON -- February 27, 2008 -- The National Institute for Health and Clinical Excellence (NICE) has a new guideline on best practice for the diagnosis and treatment of prostate cancer. The guideline, produced for NICE by the National Collaborating Centre for Cancer, will help clinicians to provide coherent and consistent care for men with suspected or diagnosed prostate cancer across England and Wales. Recommendations include: · Men with prostate cancer, as well as their partners or carers, should be informed how prostate cancer and their treatment options will affect their sexual function, physical appearance, continence, and other aspects of masculinity. Men should be supported to make treatment decisions that take into account both the effects on quality of life as well as survival. · To help men decide whether to have a prostate biopsy, healthcare professionals should discuss with them their prostate specific antigen (PSA) level, digital rectal examination (DRE) results, and comorbidities, together with their risk factors (including increasing age and black African or black Caribbean ethnicity) and any history of a previous negative prostate biopsy. The serum PSA level alone should not automatically lead to a prostate biopsy. · Men with low-risk localised prostate cancer who are considered suitable for radical treatment should first be offered active surveillance. · Healthcare professionals should ensure that men and their partners have early and ongoing access to specialist erectile dysfunction services. · Healthcare professionals should ensure that men with troublesome urinary symptoms after treatment have access to specialist continence services for assessment, diagnosis, and conservative treatment. · When men with prostate cancer develop biochemical evidence of hormone-refractory disease, their treatment options should be discussed by the urological cancer multidisciplinary team with a view to seeking an oncologist and/or specialist palliative care opinion, as appropriate. SOURCE: National Institute for Health and Clinical Excellence --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.